StockIQpro
NASDAQ:CMPX

Compass Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Compass Therapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$49.2M.Summary generated from Compass Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−41.3%
Debt / equityn/a
Free cash flow−$49.2M
FCF marginn/a
Share count changen/a

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a010
Operating income−82−42−50−57−73
Net income−82−39−42−49−66
Free cash flow−21−34−41−45−49

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)